SESSION TITLE: Mechanisms of Pulmonary Fibrosis
SESSION TYPE: Original Investigation Slide
PRESENTED ON: Sunday, April 17, 2016 at 09:45 AM - 11:15 AM
PURPOSE: To develop a lung-targeting glucocorticoid that could exert its function mainly in the lung tissues, thereby reducing the toxic side effects on other organs.
METHODS: Methylprednisolone (MPS) was used as the treatment drug, and nano-sterically stabilized liposomes (NSSLs) were used as carriers to form the MPS-NSSLs particle. The MPS-NSSLs particle was further conjugated to nanobodies of surfactant protein A (SPANb) to make MPS-NSSLs-SPANb. The characteristics of MPS-NSSLs-SPANb particles were evaluated. Small animal imaging was performed in nude mice to analyze the distribution of MPS-NSSLs-SPANb in vivo, and the content of MPS in the different organs of rats was measured at different time points to verify the lung-targeting property of MPS-NSSLs-SPANb. The safety and therapeutic effect of MPS-NSSLs-SPANb were evaluated in rats with bleomycin-induced lung injury.